Chemically triggered molecular switches for controlling the fate and function of biological systems are fundamental to the emergence of synthetic biology and the development of biomedical applications.
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So far, such chemically controlled synthetic biological switches have been reported which require the prior introduction of transgenes into the cell either by non-viral or viral vector means. 8 However, no system has been described to date, in which a conditionally controlled transgene transfer itself was used as a control point for the expression of a (therapeutic) target gene.
Controlling transgene transfer to cells in a switchable manner could be used to avoid off-target expression and thus lower the risk of side effects. Due to their high efficiency and amenability to genetic engineering, viral vectors are preferred vehicles for transferring foreign DNA into mammalian cells. 9 In particular, vectors based on the adeno-associated virus (AAV) have become popular and have recently been approved as the first gene therapeutics in the EU. 10 In this study we describe a novel strategy to control infectivity. Specifically, we report -using AAV vectors as an example -the first small molecule-triggered chemical switch that defines viral infectivity. The chemically switchable AAV SWITCH is based on an engineered serotype 2 viral capsid and on an adapter protein mediating inducible infectivity. The engineered capsid contains two modifications: (i) the capsid's natural infectivity was eliminated by mutating two key residues for AAV's primary receptor binding on target cells, a heparin sulfate proteoglycan (HSPG) structure (mutations R585A and R588A 11 in the viral capsid proteins VP1, VP2 and VP3) and (ii) the human FK-binding protein (FKBP) 12 was fused at the amino-terminal end to the viral capsid protein VP2 since it was previously shown that large insertions are tolerated at this position. 13 The adapter protein consists of a modified FKBP-rapamycin binding (FRB) domain of mTOR 14 fused to the fluorescent protein mCherry (for visualization) and a designed ankyrin repeat protein (DARPin) specific for the human epidermal growth factor receptor (DARPin EGFR 17 ). In this configuration, addition of the non-immunosuppressive and commercially available rapamycin structural analog AP21967 18 induces heterodimerization of the FRB-FKBP domains and thus the recruitment of cell-binding DARPin EGFR to the viral capsid surface, thereby restoring binding of the capsid to the cell surface and subsequent infection. However, in the absence of AP21967 the capsid cannot bind to the cell surface, thus preventing infection (Scheme 1). For the synthesis of the adapter protein, a bacterial expression vector was constructed encoding (from N-to C-terminus) the FRB domain (FRB consists of amino acids 2021-2113 of the human FRAP in which the threonine at amino acid 2098 was mutated to leucine, to accommodate the chemical substitution that prevents AP21967 binding to wild-type FRAP 18b ) fused via a glycine-serine a Faculty of Biology, University of Freiburg, Schänzlestrasse 1, 79104 Freiburg, linker to the red fluorescent protein mCherry and to DARPin EGFR . A hexahistidine tag was fused to the carboxy terminus for purification. The protein was produced in E. coli (titer: B100 mg protein per 1 L culture) and purified by immobilized metal ion affinity chromatography (IMAC, see Fig. S1 , ESI †). The functionality of the DARPin EGFR domain was confirmed by incubating the adapter protein with the EGFR-overexpressing human epidermoid carcinoma A-431 cell line for 1 h and the subsequent visualization of cell-bound mCherry via fluorescence microscopy and flow cytometry (Fig. S2 , ESI †). Confocal microscopy analysis revealed strong red fluorescence at the membrane and partly in the cytoplasm likely caused by EGFR internalization. 19 However, cells treated with an adapter protein variant lacking the DARPin EGFR domain did not show red fluorescence thereby confirming specific DARPin EGFR -mediated cell binding ( In order to confirm the functionality of the FRB domain in the adapter protein, we evaluated its AP21967-dependent binding to an FKBP protein fused to the yellow fluorescent protein mVenus (for synthesis of the FKBP-mVenus protein, see the ESI † and Fig. S1 ). To this aim, equimolar amounts of the adapter and FKBP-mVenus were mixed, incubated with or without 5-fold molar excess of AP21967 for 1 h and subsequently analyzed by size exclusion chromatography (Fig. S3 , ESI †). In the absence of AP21967, FRB-mCherryDARPin EGFR and FKBP-mVenus were both separated as monomers, while in the presence of AP21967 both proteins eluted as heterodimers thereby confirming functionality of FRB (Fig. S3 , ESI †).
Viral vector particles with an engineered capsid were produced by the adenovirus helper-free AAV serotype-2 packaging system (Fig. 1a) . 20 In order to eliminate natural infectivity, arginines 585 and 588 of the viral capsid proteins VP1, VP2 and VP3 were mutated to alanine (HSPG-ko mutation). 11 Furthermore, a silent mutation was introduced within the VP2 start codon T138 of the rep-cap plasmid to prevent translation of the unmodified VP2 protein (plasmid pRCVP2koA). The gene encoding the fusion protein FKBP-VP2/HSPG-ko was expressed in trans from a separate vector (plasmid pMH156). 13, 21 In order to visualize viral infection, a vector genome was used encoding an expression cassette for the green fluorescent protein (plasmid pCMVgfp). These plasmids were transfected into human embryonic kidney cells (HEK-293T) together with an adenovirus-derived helper plasmid (pHelper), and viral vector particles were isolated by cell lysis and subsequent purification by ultracentrifugation on an iodixanol density gradient. The viral titer was determined by quantitative genomic PCR and revealed 4.1 Â 10 11 genomic copies per mL vector stock.
Incorporation of the engineered proteins into the viral capsid was analyzed by SDS-PAGE and Western blotting revealed the expected presence of the VP1 and VP3 HSPG-ko variants and of the FKBP-VP2/HSPG-ko fusion protein (Fig. 1b) .
Based on the successful synthesis and characterization of the adapter protein and the engineered viral capsid, we evaluated the functionality of AAV SWITCH . To this aim, 4.8 Â 10 4 A-431 cells were seeded per well (volume: 600 ml), incubated overnight and subsequently supplemented with 10 À7 M adapter protein, 3.3 Â 10 4 viral vector particles per cell (based on genomic copy number) and optionally with 1 mM AP21967. After 48 h, infection was analyzed by visualizing the expression of the vector-encoded reporter gene g fp by confocal microscopy (Fig. 2a) . Under both conditions (with and without AP21967) binding of the adapter protein to cells was confirmed by membrane-and cytoplasm-localized red fluorescence. However, only in the presence of AP21967, green fluorescent cells were observed indicating the functionality of the chemically switchable viral vector AAV SWITCH (Fig. 2a) .
The performance of the chemically switchable infection was quantified by flow cytometry in the absence and presence of the adapter protein and using different vector doses (Fig. 2b and Fig. S4, ESI †) . In the absence of the adapter, only background GFP levels were detected reflecting the efficacy of the HSPG-ko mutation to ablate natural viral tropism. In the presence of the adapter protein and the viral vector particles but without AP21967, GFP levels similar to those of the adapter-lacking controls were observed. However, upon addition of the chemical inducer AP21967 (1 mM), a more than 50-fold increase in GFP levels was observed thereby confirming the previous qualitative microscopy analysis (Fig. 2a) and the functionality of the AAV SWITCH system. The relative gene-delivery efficiency of AAV SWITCH in the AP21967-induced state was in the same range (75-85%, Fig. S5 , ESI †) as that of AAV-2 vectors with unmodified capsids using the same number of viral vector particles per cell.
To show that AAV SWITCH is specific for EGFR-overexpressing cells, the system was tested with five other cell lines reported to express EGFR at different levels ( In this study we describe the first viral system with chemically switchable infectivity. This system perfectly complements previously developed synthetic biological switches for controlling intracellular processes.
1e,4 While all these switches focus on transgene systems already installed into the cell, AAV SWITCH allows for the first time the direct chemically switchable control of the gene transfer process itself based on highly efficient viral vectors. 31 Beyond the described specific implementation of AAV SWITCH , we assume that the herepresented approach is likely generically applicable to different viral vector systems, target cell lines and chemical inducers by modularly exchanging the dimerizer modules or the cell-binding domain. The concept presented in this study thus represents a blueprint for obtaining a time-resolved control of the cell specificity of viral vectors in order to precisely target molecular interventions in future synthetic biological devices and gene therapy scenarios.
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